|
|
Article: Results of Trial with COZAAR in Patients with Acute Myocardial Infarction Presented at European Society of Cardiology.
- Article from:
- Business Wire
- Article date:
- September 2, 2002
CopyrightCOPYRIGHT 2002 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health & Pharmaceutical Writers
BERLIN--(BUSINESS WIRE)--Sept. 2, 2002
Results of a large clinical trial comparing COZAAR(R) (losartan potassium tablets) to captopril, an angiotensin converting enzyme (ACE) inhibitor, in the treatment of patients with acute myocardial infarction (commonly known as a heart attack) were presented today at the Congress of the European Society of Cardiology (ESC).
The 5,477 patient randomized, double-blind study -- the Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan (OPTIMAAL) -- was designed to determine if COZAAR would be either superior or non-inferior to an ACE ...